The clinical application of class 3.1 hepatitis C drug sofibvir of Kelun Pharmaceutical Co., Ltd. was accepted

The drug is regarded as a breakthrough drug for the treatment of hepatitis C, and the product was approved for marketing at the end of 2013, with sales revenue of US $8.67 billion as of the third quarter of 2014 Some analysts predict that the product is expected to sell more than 10 billion dollars this year, making it the fastest super product in history to sell 10 billion dollars a year CFDA website information shows that at present, there is no manufacturer of API and tablet in China In addition to Kelun pharmaceutical industry, sinogy Pharmaceutical Technology (Shijiazhuang) Co., Ltd of Shiyao group has also applied for clinical trials of the drug According to the public information, sofosbuvir was acquired by Gilead in 2011 by purchasing pharmaset, and approved by the US FDA and EU respectively in December 2013 and January 2014 It is the first drug that can be used in the whole oral treatment of hepatitis C Before that, patients with hepatitis C must be treated for at least six months, including the injection of interferon and ribavirin, which can cause serious flu like symptoms and side effects such as rash and anemia, respectively The cure rate of these regimens in clinical trials was 75%, while the cure rate of sufebuvir was more than 90% Kelun Pharmaceutical Co., Ltd is a leading infusion company in China Since 2013, the company has actively promoted the research and development of new drugs, and actively arranged product lines such as anti-tumor, diabetes and off-site nutrition According to the company's 2013 annual report, in 2013, the company applied for 55 projects, including 42 class a projects; 155 class a projects are under research, including 48 super class a projects In 2013, the company invested more than 400 million yuan in R & D, an increase of 99.74% year on year, accounting for 5.86% of the operating revenue.